Purpose: The first reports of hepatic steatosis following pancreaticoduodenectomy (PD) were published several years ago; however, clear risk factors remain to be identified. Therefore, the aim of this study was to identify the risk factors for hepatic steatosis post-PD. Methods: We studied 90 patients who had undergone PD between September 2005 and January 2015. The inclusion criteria were as follows: available unenhanced CT within one month before PD and at least one unenhanced CT acquisition between PD and chemotherapy initiation. Using scanners, we studied the liver and spleen density as well as the surface areas of visceral (VF) and subcutaneous fat (SCF). These variables were previously identified by univariate and multivariate analyses. Results: Hepatic steatosis occurred in 25.6% of patients at 45.2 days, on average, post-PD. Among the patients with hepatic steatosis, the average liver density was 52 HU before PD and 15.1 HU post-PD (p < 0.001). The Patients with hepatic steatosis lost more VF (mean, 28 vs. 11 cm 2 ) and SCF (28.8 vs. 13.7 cm 2 ) (p < 0.01 and p = 0.01, respectively). Portal vein resection and extensive lymph node dissection were independent risk factors in the multivariate analysis (odds ratio [OR] 5.29, p = 0.009; OR 3.38, p = 0.04, respectively). Conclusion: Portal vein resection and extensive lymph node dissection are independent risk factors for post-PD hepatic steatosis.
Hepatic steatosis is a well-known complication of pancreaticoduodenectomy (PD, Whipple's procedure) [1] ; however, its underlying mechanism is unclear. PD has been used for many years to treat various lesions of the pancreatic head or periampullary region, especially adenocarcinoma of the pancreatic head. Many specialized centers now achieve morbidity rates of less than 40% and mortality rates of less than 5% [2] [3] [4] . With this decrease in early postoperative complications, a growing number of patients are surviving for many years (20-30% at 5 years) [3, 5] . However, depending on the series, between 8 and 40% of patients develop hepatic steatosis post-PD [6] [7] [8] [9] [10] . Post-PD hepatic steatosis is generally considered a mild condition, although it can lead to secondary liver dysfunction [7, [11] [12] [13] and presents a risk of progression to cirrhosis and hepatocellular carcinoma [14] . In addition, hepatic steatosis makes it difficult to identify early metastases in the liver parenchyma [15, 16] .
Liver biopsy is the gold-standard method for diagnosing hepatic steatosis [17, 18] , although it is only performed if the results are likely to influence treatment. Computed tomography (CT) and magnetic resonance imaging (MRI) are two widely available, non-invasive imaging methods for assessing hepatic steatosis [18] . The purpose of this study was to identify risk factors for hepatic steatosis following PD.
Methods
Our ethics committee did not require specific authorization for obtaining and processing patient data in an observational retrospective study.
Patients
This retrospective study included patients that underwent PD that was performed at our institution between September 2005 and January 2015.
The inclusion criteria were as follows:
available unenhanced CT within one month before PD; and at least one unenhanced CT acquisition between PD and chemotherapy initiation.
The following exclusion criteria were applied:
hepatic steatosis upon preoperative CT; and prior splenectomy (ruling out a comparison of liver and spleen density).
A total of 90 patients were included ( Fig. 1 flowchart) .
Data collection General data
The following data were collected for each patient: age at PD, sex, weight, height, BMI, date of PD, adjuvant chemotherapy (yes/no), chemotherapy start date, number of CT acquisitions between PD and chemotherapy, and histology of the surgical specimen.
The following information was extracted from the surgical records: the pancreatic-enteric anastomosis type (pancreatogastrostomy or pancreatojejunostomy), extensive vs. non-extensive lymph node dissection (extensive lymph node dissection was defined as an exposure of the right lateral surface of the celiac trunk and the superior mesenteric artery [SMA] coupled with dissection below the left renal vein [interaortocaval]), and venous resection (yes/no).
CT analysis of steatosis
The CT images analyzed in this study were acquired on a 64-detector-row device (GE VCT Lightspeed, Milwaukee, WI, USA) with the following settings: 200-700 mAs, 100-120 kV, 0.6 s rotation, 3 mm collimation, and 40 mm detector coverage.
The signs of steatosis were sought upon acquisition without contrast injection using Liver analysis CT Synapse PACS of Fujifilm Medical Systems (Tokyo, Japan). Three regions of interest (ROIs) were defined: two regions of interest (ROI) in the liver, in the same place for each CT scan (one in the left lobe [segment II] and the other in the right lobe [segment VIII]), and one ROI in the spleen. Each ROI was a circular area with a diameter of 15 mm ( Fig. 2A measurements before PD). The average density of each ROI was expressed in Hounsfield units (HU). The liver density was calculated as the average density of the two ROIs. A patient was considered to have hepatic steatosis when the difference between the liver (average of the two ROIs) and spleen was at least -10 HU and when the liverspleen ratio was less than 0.9 [19] [20] [21] (Fig. 2B hepatic steatosis post-PD). Group A corresponded to patients with hepatic steatosis post-PD, and group B corresponded to patients without hepatic steatosis post-PD. Steatosis was qualitatively characterized as homogenous (diffuse, affecting the entire liver parenchyma) or heterogeneous (alternating areas of steatosis and healthy liver).
These measurements were performed on all of the CT acquisitions before PD (n = 90) and on all of the acquisitions that were obtained between PD and chemotherapy initiation (n = 153), with an average of 2.7 acquisitions per patient. The time to steatosis was measured in days from the date of surgery to the first detection of a difference in a follow-up CT scan.
We have analyzed the loss of visceral fat (VF) and subcutaneous fat (SCF) during the period between PD and chemotherapy. VF and SCF were quantified by determining the respective surface areas on a reference section through the L3-L4 intervertebral disc [22, 23] ; these values are known to strongly correlate with the total volumes of VF and SCF [22] [23] [24] . The surface areas of VF and SCF (in cm 2 ) were determined for each of the 243 pre-and postoperative acquisitions using dedicated software (Fujifilm 3D Synapse) for semi-automatic detection with a fixed attenuation range of -190 to -30 HU as the reference standard [21] [22] [23] . (Figure 3 measurements of VF and SCF).
Statistical analysis
Descriptive analyses used the mean (±standard deviation) and the median (percentage). Quantitative variables were analyzed using Student's t test, and qualitative variables were analyzed using Wilcoxon's nonparametric test and Fisher's exact test. The multivariate analysis was based on logistic regressions, and p values <0.05 were considered statistically significant.
All of the analyses were performed using SAS software v 9.3 (SAS Institute Inc., Cary, NC, USA).
Results

Clinical characteristics
The study population consisted of 31 women (34.4%) and 59 men (65.6%). The mean age of the patients at the time of B Unenhanced CT 59 days after PD. Note the marked diffuse liver hypodensity corresponding to hepatic steatosis with average attenuation values of -33 and -33 HU for the liver and 51 HU for the spleen (liver-spleen differences = 80.5 HU). PD was 63.9 years (range, 40-87 years), the mean body mass index was 25.3 kg/m 2 , and 9 patients had a diabetes.
Lesion histology
Adenocarcinoma of the pancreatic head was the most common lesion type (50 patients, 55.5%), followed by distal cholangiocarcinoma (9 patients, 10%), ampullary adenoma (9 patients, 10%), neuroendocrine tumor (6 patients, 6.7%), adenocarcinoma of the duodenum (5 patients, 5.6%), intraductal papillary mucinous neoplasm of the pancreas (IPMN; 4 patients, 4.4%), focal chronic pancreatitis (4 patients, 4.4%), mucinous cystadenoma (2 patients, 2.2%), and duodenal villous tumor (1 patient, 1.1%). 
Surgical data
Hepatic steatosis
The average liver density in the entire population decreased post-PD, whereas the spleen density remained stable. At an individual level, the liver density decreased in 23 patients, although their spleen density was roughly stable. Both the liver-spleen difference and the liver-spleen ratio decreased in these 23 patients (25.6%), who corresponded to group A. The remaining 67 patients (74.4%) without hepatic steatosis corresponded to group B. For the patients in group A, the mean liver density was 52 HU before PD and decreased by an average of 15.1 HU post-PD (p < 0.001). For the patients in group B, the mean liver density was 52.5 HU before PD and remained stable after PD (average, 53.6 HU) (p = 0.35). Consequently, the liver-spleen difference and ratio both decreased significantly post-PD (Table 1) .
Hepatic steatosis was uniform and diffuse in all 23 patients, and no cases of heterogeneous steatosis were observed. The mean duration between preoperative CT scan and surgery was 6 days (1-22 days) for the group A, and 9 days (1-27 days for the group B. The average time to onset of hepatic steatosis post-PD was 45.2 days (standard deviation (SD), 30.1 days; range, 3-128 days). The total number of post-PD acquisitions (before chemotherapy) was 143, including 42 acquisitions for group A (n = 23) and 111 acquisitions for group B (n = 67). The patients developed steatosis 45, 2 days post-PD (40-139 days) on average. Chemotherapy was not administered to the 4 patients who developed steatosis (1 ampullary adenoma, 1 chronic pancreatitis, 1 IPMT, and 1 adenocarcinoma of the pancreatic head with postoperative complications that delayed chemotherapy) and to the 19 patients who did not develop steatosis (8 ampullary adenoma, 3 chronic pancreatitis, 3 IPMT, 2 mucinous cystadenoma, 1 villous tumor of the duodenum, and 2 adenocarcinomas of the pancreatic head with postoperative complications that delayed chemotherapy).
Visceral and subcutaneous fat
Before PD, significant differences in the surface area of visceral and subcutaneous fat were not observed between the patients who did and did not develop steatosis (p = 0.13 and p = 0.52, respectively) ( ) between the pre-PD scan and the post-PD scan that presented the lowest liver densities (<2 months, average 48 days) (p < 0.01 and p = 0.01, respectively). Risk factors for hepatic steatosis (Table 3) Age, sex, bodyweight, BMI, diabetic status, anastomosis type, and histological type did not influence the risk of post-PD steatosis. Extensive lymph node dissection was performed in 60.9% of the patients in group A and in 19.4% of the patients in group B (p < 0.001). Portal vein resection was performed in 52.2% of the patients in group A and in 10.4% of the patients in group B (p < 0.001).
Multivariate analysis revealed that portal vein resection and extensive lymph node dissection were independent predictors of post-PD hepatic steatosis. The risk of developing hepatic steatosis increased by 5.3-fold with vein resection and by 3.4-fold with extensive lymph node dissection (Table 4) .
Discussion
Post-PD hepatic steatosis was frequent. This condition has not been reported after other gastrointestinal surgeries (surgery of the esophagus, stomach, and colon, among others) or even after partial pancreatic resections, such as left splenopancreatectomy, left pancreatectomy, or central pancreatectomy [25, 26] ; therefore, it seems to occur exclusively post-PD.
The CT images acquired between surgery and chemotherapy initiation indicated that hepatic steatosis occurred after a mean period of 45.2 days (SD 30.1 days). We restricted our analysis to CT images that were acquired before chemotherapy because certain chemotherapeutic agents, such as 5-fluorouracil and platinum derivatives, could potentially cause hepatic steatosis by subjecting both malignant and normal cells to oxidative stress [27, 28] .
Factors that have been previously implicated in the onset of steatosis in this setting include exocrine pancreatic insufficiency [10] , pancreatic fistula [29] , pancreatic adenocarcinoma [30, 31] , pancreatic resection lines [31] , postoperative diarrhea [31] , blood loss [32] , and chemotherapy [27, 28] ; however, none of these factors Female gender was reported to be a risk factor by Miura et al. [13] and Ivanics et al. [33] , although this finding was not confirmed by Okamura et al. [10] or Nakagawa et al. [34] and is not supported by our results because 47.8% and 29.9% of our patients with and without steatosis were female, respectively (p = 0.13).
The specific nutrition provided during postoperative ICU stays might be inculpatory [35] ; however, such diets are identical to that used after surgery for other GI malignancies (e.g., malignancies of the esophagus or stomach). In addition, the nutrition administered following pancreatic surgery has been standardized for several years [36, 37] and is similar for all patients, although steatosis only occurs in 40% of cases. In addition, the time to steatosis onset (average, 45 days) does not favor a role of postoperative ICU nutrition, which usually lasts only 48 h [37] . Partial pancreatic resection can result in glucose intolerance (termed ''pancreatogenic diabetes'') [38] , a disorder distinct from type 1 and 2 diabetes; however, this complication has not been identified as a risk factor for steatosis [1, 29] .
To the best of our knowledge, the possible role of extensive lymph node dissection in the onset of post-PD hepatic steatosis has not been previously examined. However, this particular modality of lymph node dissection is only used during PD (and occasionally during the excision of tumors with retroperitoneal extension) to avoid local or lymph node recurrence [2, [39] [40] [41] . ''Regional'' lymph node dissection is recommended in this setting along with the excision of the anterior and posterior peri-pancreatic nodes, the hepatic common and proper nodes, and the nodes located at the right-hand edge of the celiac trunk and the SMA, and if necessary, these procedures are coupled with interaortocaval lymph nodes dissection [42, 43] .
We found that two factors were independently associated with post-PD hepatic steatosis: portal vein resection (odds ratio This type of extensive node dissection may also have other consequences. Indeed, most of our patients experienced a rapid loss of VF and SCF post-PD; however, these losses were greater in patients who went on to develop steatosis (SCF: -28.82 vs. -13.74 cm 2 , p = 0.01; VF: -27.96 vs. -11.0 cm 2 , p < 0.01). We suspect that post-PD hepatic steatosis may be caused by a cascade of events that is triggered by this specific type of node dissection. Physiologically, the small intestine is the sole site of lipid absorption, and the pancreas is virtually the only source of lipolytic enzymes [44] . Most nutrients are absorbed through the villous mucosa into blood capillaries, with the noteworthy exception of long-chain fatty acids. Bile salts are necessary for the formation of chylomicrons, which cannot cross the basement membrane of the blood vessels or enter the more permeable lacteal lymphatics. This chyle then flows to the intestinal trunk, which represents the first section of the thoracic duct and which is one of the three constituents of the cisterna chyli (also composed of the right and left lumbar trunks).
The intestinal trunk (or cisterna chyli) is likely to be severed during extensive lymph node dissection, which includes the right-hand edge of the superior mesenteric artery, thereby preventing long-chain fatty acids from entering the lacteal lymphatics and thus steatorrhea. This deficit of long-chain fatty acids is compensated by two mechanisms (long-chain fatty acid mechanism) [45] [46] [47] : the use of reserves by a peripheral lipolysis (which would explain the greater loss of VF and SCF in group A) and de novo synthesis by the liver; both mechanisms cause hepatic steatosis.
Individual anatomic variations (e.g., double cisterna chyli or multiple intestinal trunks) are particularly numerous in the lymphatic network [48] [49] [50] [51] , which might explain why certain patients do not develop steatosis after extensive lymph node dissection. In contrast, the onset of steatosis in patients who have not had extensive lymph node dissection might be caused by sectioning the lymphatic trunk in an unusual location. Post-PD steatosis regressed in half of our patients after an average of 6.2 months. This regression could be linked to the regeneration of the remaining lymph vessels, which would restore drainage in the affected region, as observed following breast tumor excision with node dissection [52] and following surgery for endometrial cancer with extensive retroperitoneal dissection, possibly causing reversible chylous ascites [53, 54] .
Furthermore, the patients in group A who underwent portal vein resection had an extensive lymph node dissection.
Our study had several limitations. First, this study was a single-center retrospective study, and CT was performed at variable times in the interval between surgery and adjuvant chemotherapy. This variation might have influenced the estimated time to steatosis onset, although it is noteworthy that the CT images were acquired within a 15-day period in all of the patients. Second, we did not consider pancreatic fistulae or the extent of pancreatic resection, and both may play a role in the onset of steatosis [29, 31] . Third, we used a radiological method to diagnose hepatic steatosis and may have overlooked mild cases that were only detectable by biopsy. A prospective preoperative/postoperative anatomical study of the different lymphatic trunks that utilize lympho-MRI is required to confirm these hypotheses. Indeed, we could predict the risk of the following side effects prior to surgery: hepatic steatosis, VF loss, SCF loss, and steatorrhea. These predictions can be determined based on the physiopathology according to the anatomical variants and to the extensiveness of the lymph node. For example, the surgeon should be extremely careful to determine whether a patient has an extensive lymph node and a lymphatic trunk in an unusual location. Following surgery, the extent of lymphatic resection can be compared with the preoperative lympho-MRI.
Conclusion
This study shows that portal vein resection and extensive lymph node dissection significantly increase the risk of hepatic steatosis post-PD. A follow-up with nutritionists immediately after the surgery may be crucial for these patients. A preoperative lympho-MRI would be necessary to identify possible anatomical variants that require modification of the lymph node dissection procedure, and a lympho-MRI post-operation would be needed to confirm our hypothesis.
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